01—Abstract
Summary
Summary of the 10-Q filed August 4, 2025. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. reported strong performance for the first half of 2025, with net revenues reaching $28.8 billiona, a 7.4% increase year-over-year, driven by robust growth in its immunology portfolio, particularly Skyrizi and Rinvoq, which saw increases of 65.8% and 48.5% respectively.
Despite a significant decline in Humira sales due to biosimilar competition, the company's diversified revenue streams and successful new product launches have offset this impact. Operating earnings for the period were $8.6 billionb, demonstrating solid profitability. The company continues to strategically invest in its pipeline, announcing significant advancements and new licensing agreements in areas like obesity, neuroscience, and oncology.
AbbVie also made considerable progress in managing its financial resources, generating $6.8 billionc in operating cash flow and actively managing its debt and capital structure. The company declared a quarterly cash dividend of $1.64 per share, underscoring its commitment to returning value to shareholders.
02—Key points
Key Highlights
- Total net revenues grew 7.4% to $28.8 billion for the first six months of 2025, compared to the same period in 2024.
- Skyrizi and Rinvoq demonstrated substantial growth, with net revenues increasing by 65.8% and 48.5% respectively, signaling strong market adoption.
- Humira's net revenues declined by 54.3%, reflecting the ongoing impact of biosimilar competition.
- Operating earnings reached $8.6 billion for the first six months of 2025.
- AbbVie announced significant pipeline advancements and strategic acquisitions/licensing agreements, including entry into the obesity market with the Gubra collaboration.
- Cash flow from operations was robust at $6.8 billion for the first six months of 2025.
- The company declared a quarterly cash dividend of $1.64 per share, reflecting continued commitment to shareholder returns.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, AbbVie Inc. kept $0.06.
- Revenue$15.42B100.0%
- Cost of revenue−$4.35B28.2%
- Gross profit$11.08B71.8%
- Operating costs−$6.18B40.1%
- Operating income$4.89B31.7%
- Interest, other & tax−$3.96B25.7%
- Net income$938.0M6.1%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 4, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $15.42B$14.46B | +6.6% |
| Cost of Revenue | $4.35B$4.20B | +3.4% |
| Gross Profit | $11.08B$10.26B | +8.0% |
| SG&A Expenses | $3.25B$3.38B | −3.7% |
| Operating Expenses | $10.53B$10.46B | +0.6% |
| Operating Income | $4.89B$4.00B | +22.4% |
| Interest Expense | $740.00M$726.00M | +1.9% |
| Net Income | $938.00M$1.37B | −31.5% |
| EPS (Basic) | $0.52$0.77 | −32.5% |
| EPS (Diluted) | $0.52$0.77 | −32.5% |
| Shares Outstanding (Basic) | 1.77B1.77B | 0.0% |
| Shares Outstanding (Diluted) | 1.77B1.77B | 0.0% |
05—Questions
Frequently Asked Questions
What was the primary driver of AbbVie's revenue growth in the first half of 2025?
The primary driver of AbbVie's revenue growth in the first half of 2025 was the strong performance of its immunology products, Skyrizi and Rinvoq, which experienced significant year-over-year increases in net revenues. These gains helped offset the decline in Humira sales.
How is AbbVie managing the decline in Humira sales?
AbbVie is managing the decline in Humira sales, which is attributed to biosimilar competition, by focusing on its diversified portfolio and the growth of newer products like Skyrizi and Rinvoq. The company is also investing in its pipeline to develop future growth drivers.
What are some of AbbVie's recent strategic moves in pipeline development?
AbbVie has been active in expanding its pipeline through acquisitions and licensing agreements. Notable recent activities include the proposed acquisition of Capstan Therapeutics for an in vivo targeted CAR-T therapy, the acquisition of Nimble Therapeutics for oral peptide therapeutics, and a licensing agreement with Gubra A/S to enter the obesity market.
How did contingent consideration impact AbbVie's financial results?
Changes in the fair value of contingent consideration liabilities had a significant impact on AbbVie's financial results, contributing $4.3 billion to 'Other expense, net' in the first six months of 2025. This was primarily driven by higher estimated Skyrizi sales, the passage of time, and lower discount rates.
06—Continue